Omeros Corporation
201 Elliott Avenue West
Seattle
Washington
98119
United States
Tel: 206.676.5000
Fax: 206.676.5005
Website: https://www.omeros.com/
Email: hr@omeros.com
About Omeros Corporation
At Omeros, we are proud of our innovative and cutting-edge science. Our world-class team has achieved scientific advances that no other group has been able to accomplish, delivering wholly new classes of therapeutics to benefit patients. We let science lead the way.
From our foundation of groundbreaking science, we continue to build and advance a deep and diverse pipeline of small-molecule and protein therapeutics. We are not interested in developing “me-too” products; instead, we are focused on tackling challenging diseases and disorders with significant unmet medical needs. The result is an exciting pipeline of first-in-class drugs with new mechanisms of action that target previously untapped receptors and enzymes.
The Omeros team is exceptionally talented, passionate, collaborative and diverse. We hire smart, creative and hard-working people who want to play a meaningful part in building a preeminent biopharmaceutical company. We come from all corners of the globe, bringing unique abilities and experiences together to provide hope to patients and their families.
459 articles about Omeros Corporation
-
Omeros Corporation Reports Second Quarter 2010 Financial Results
8/11/2010
-
Omeros Corporation to Webcast Presentation at Canaccord Genuity 30th Annual Growth Conference
8/5/2010
-
Omeros Corporation Secures $40 Million Committed Equity Financing Facility
7/29/2010
-
Omeros Corporation Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
7/27/2010
-
Omeros Corporation Successfully Unlocks Orphan GPCRs
6/29/2010
-
Omeros Corporation Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
5/13/2010
-
Omeros Corporation Reports First Quarter 2010 Financial Results
5/13/2010
-
Omeros Corporation Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
5/3/2010
-
Omeros Corporation to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
4/29/2010
-
Omeros Corporation Reports Fourth Quarter and Year-End 2009 Financial Results -Company Also Announces Two Additions to Management Team
4/1/2010
-
Omeros Corporation to Host Conference Call on Fourth Quarter and Full Year 2009 Results on March 31
3/15/2010
-
Omeros Corporation Licenses PDE7 Compounds for Parkinson's Disease Program
3/9/2010
-
Omeros Corporation Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
1/29/2010
-
Omeros Corporation Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
1/28/2010
-
Daniel K. Spiegelman Elected to Board of Directors of Omeros Corporation
12/9/2009
-
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
11/20/2009
-
Omeros Corporation, First U.S. Biotech IPO Since February 2008, Sees Shares Drop 13 Percent in First Day
10/9/2009
-
Omeros Corporation Raises $68.2M in Washington's First IPO in Two Years
10/8/2009
-
Omeros Corporation Announces IPO of 6.8 Million Shares
9/18/2009
-
Omeros Corporation Moves Closer To IPO, Sets Price Goal
9/17/2009